OncoMatch/Leukemia — Acute Myeloid (AML)/IDH2
Leukemia — Acute Myeloid (AML)IDH2 Clinical Trials
IDH2 mutations occur in approximately 12% of AML and produce 2-hydroxyglutarate via the same mechanism as IDH1 mutations, impairing normal differentiation. Enasidenib is FDA-approved as monotherapy for relapsed/refractory IDH2-mutant AML; vorasidenib (a brain-penetrant pan-IDH inhibitor) is approved for IDH-mutant glioma. Trials investigate enasidenib combinations with venetoclax and hypomethylating agents and pan-IDH inhibitor strategies covering both IDH1 and IDH2 mutations in AML.
Top recruiting IDH2 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Hutchmed
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Alice Mims
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center